- Laxxon Medical has developed a technology to mass produce 3D structured pills
- Controlled release of active ingredients limits side effects
- Multiple ingredients can be combined into one pill so daily doses can be reduced to fewer pills
Essen, Germany. Evonik Venture Capital has invested in Laxxon Medical. The Nevada, U.S.-based company has developed a 3D screen printing technology for the manufacture of structured tablets that enables the controlled release of active pharmaceutical ingredients over time. Multiple ingredients can also be combined into one pill. Evonik’s specialized polymers ensure targeted delivery of the active ingredients in the novel tablets.
“This technology is great for patients. We expect fewer side effects from a more controlled drug delivery and having fewer pills reduces the risk of forgetting doses during the day,” said Bernhard Mohr, head of Evonik Venture Capital. “We are pleased to support innovation that brings real benefits to people and their health.”
Laxxon’s 3D screen printing gives the tablets different layers. The inner structure of the pill can, for example, have alternative layers of active ingredient and inert layers. This design allows for several doses of the drug to be released over time. In another design multiple drugs can be layered on top of each other, thus combining several pills into one. The size, geometry, inner structure, and materials used all combine to allow ideal kinetics – the speed of chemical reactions in the body - for the release of the active ingredients.
Another benefit of the technology is the speed of printing, which is significantly faster than established 3D printing processes allowing mass production. The new technology could generate opportunities to extend patents for pharmaceutical companies because of improved drug delivery.
Evonik has 60 years of experience with drug delivery systems. The company makes excipients - an inactive substance that serves as the vehicle for a drug. For example, polymers serve as a coating for tablets allowing for the active ingredient to be released either immediately after being swallowed or after a certain delay or providing a sustained release over time.
Evonik’s products will be used in Laxxon’s printing pastes. In addition, Evonik and Laxxon have signed a joint product development and cooperation agreement. Based on this agreement, Evonik intends to manufacture tablets for Laxxon.
The technology is relevant to Evonik’s innovation growth fields Healthcare Solutions and Additive Manufacturing. “Drug delivery is becoming more high-precision and increasingly targets specific patient groups,” said Thomas Riermeier, head of Evonik’s Heath Care business line. “The collaboration with Laxxon will allow us to accelerate our activities in this important and emerging market.”
Laxxon was founded in 2017 by Helmut Kerschbaumer, Klaus Kuehne and Achim Schneeberger in Switzerland and is since 2021 headquartered in the U.S. with a German and a Swiss subsidiary.
“Evonik is the perfect partner to support the development of tablets with unique release properties,” said Kerschbaumer, who is also chief executive officer of Laxxon. “We are happy to have one of the world’s leading specialty chemicals companies with which we can further develop our products and at the same time commercially manufacture them.”
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Evonik Venture Capital
With a fund size of €250 million, Evonik Venture Capital (EVC) has made about 45 investments since 2012, both direct and fund investments. EVC has offices in Germany, the USA and China and invests in innovative technologies and disruptive business models in the fields of Nutrition & Care, Specialty Additives and Smart Materials, as well as enabling digital technologies. The EVC team of experienced investment managers provide portfolio companies comprehensive support. The investment scope ranges from early stage to growth stage with investment volume per portfolio company of up to €15 million. https://venturing.evonik.com
About Laxxon Medical Corporation
Laxxon Medical holds the exclusive worldwide rights to the patented use and application of 3D screen printing technology for the development, manufacture and commercialization of pharmaceutical dosage forms. With Laxxon Medical's innovative SPID®-Technology (Screen Printing Innovational Drug Technology), it is possible for the first time to develop oral, transdermal and implantable dosage forms through geometric shaping and heterogeneous distribution of active ingredients within the printed units yielding dosage forms with tailored release of active ingredients. To learn more about Laxxon Medical's disruptive 3D screen printing technology, visit www.laxxonmedical.com
Contact: Frances Hoggard, Public Relations Manager, email@example.com
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.